Glucose Fresenius Kabi

Glucose Fresenius Kabi is an intravenous solution containing glucose monohydrate as the active ingredient; the product’s strength and concentration are not specified in the available data, and it is supplied as a sterile parenteral fluid for clinical use in the European market. It is intended for administration by healthcare professionals under controlled conditions and is classified as an excipient/carbohydrate solution within the parenteral nutrition and fluid replacement therapeutic categories.

Glucose Fresenius Kabi is used in clinical settings to provide rapid carbohydrate supplementation and to support fluid balance when oral intake is insufficient or contraindicated.

- Treatment of hypoglycemia when intravenous glucose is required. - Component of parenteral nutrition regimens to supply caloric energy. - Fluid and electrolyte replacement in perioperative or critical‑care patients. - Dilution medium for compatible intravenous medications. - Support for patients with prolonged fasting or malnutrition. - Maintenance of blood glucose levels during insulin therapy adjustments.

When administered intravenously, glucose solutions can produce a range of physiological responses. Most are mild and transient, while rare events may require medical attention.

Common: - Transient hyperglycemia that resolves with monitoring. - Mild nausea or vomiting. - Local irritation or erythema at the infusion site. - Electrolyte shifts such as mild hypokalemia.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypotension from rapid infusion of large volumes. - Allergic or anaphylactic reactions. - Metabolic acidosis in patients with impaired metabolism.

Glucose Fresenius Kabi should be administered only after evaluating the patient’s clinical status and laboratory values to avoid complications.

- Verify blood glucose level before infusion to prevent excessive hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency. - Use aseptic technique to maintain sterility of the solution. - Monitor electrolytes, especially potassium and phosphate, during prolonged therapy. - Avoid rapid administration of large volumes to reduce risk of circulatory overload. - Consider compatibility with other IV drugs; incompatibility may cause precipitation.

Glucose solutions can interact with other intravenous agents or affect metabolic pathways, requiring careful coordination with concurrent therapies.

Avoid: - Co‑administration with high‑dose insulin without appropriate glucose monitoring. - Mixing with calcium‑containing solutions that may precipitate. - Simultaneous infusion with certain parenteral lipid emulsions that can cause phase separation.

Use with caution: - Concurrent use of diuretics that may exacerbate electrolyte disturbances. - Administration alongside catecholamines, which can increase glucose production. - Patients receiving beta‑blockers, as hypoglycemia symptoms may be masked.